Korro Bio Business Summary

Korro Bio, Inc. (KRRO) is a clinical-stage biopharmaceutical company that generates revenue through strategic research collaborations, licensing agreements, and milestone payments, highlighted by a 2024 partnership with Novo Nordisk valued at up to $530 million. The company’s business model is centered on its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform, which co-opts the body’s natural ADAR enzymes to perform precise, transient single-base RNA edits without altering the underlying DNA. Its primary business segments focus on the development of genetic medicines for rare and prevalent diseases, led by its flagship program KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) and a pipeline targeting cardiometabolic and CNS disorders. Korro competes directly with Beam Therapeutics, Wave Life Sciences, and ADARx Pharmaceuticals in the genetic medicine landscape. Relative to these peers, Korro differentiates itself by offering a tunable, non-permanent therapeutic approach that leverages established oligonucleotide delivery modalities to address previously undruggable genetic targets. Korro Bio was founded in 2018 by a veteran team including Nessan Bermingham, Josh Rosenthal, Jean-Francois Formela, and Andrew Fraley. The company is currently led by CEO and President Ram Aiyar, Ph.D., MBA, who also serves as the interim Chief Financial Officer following the late 2025 resignation of Vineet Agarwal; Aiyar’s pedigree includes co-founding Corvidia Therapeutics, which was acquired by Novo Nordisk for $2.1 billion. The executive leadership team is further comprised of Chief Scientific Officer Loic Vincent, Ph.D., Chief Operating Officer Todd Chappell, and Co-founder and CTO Andrew Fraley. The company is backed by a high-density roster of institutional investors, including Atlas Venture, New Enterprise Associates (NEA), Fidelity Investments, and Point72 Asset Management, with strategic investment from Eli Lilly. The Board of Directors, chaired by Nessan Bermingham, includes prominent industry figures such as Ali Behbahani of NEA and clinical expert Katharine Knobil.